BSX|Analyst Targets
BSX|Company Info
BSX|Insider Trading
BSX|Fundamentals
BSX|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q4'26 | $0.78 | - | - |
| Q3'26 | $0.72 | $0.73 | +0.9% |
| Q2'26 | $0.83 | $0.86 | +3.9% |
| Q1'26 | $0.79 | $0.80 | +1.6% |
| Q4'25 | $0.79 | $0.80 | +1.6% |
| Q3'25 | $0.71 | $0.75 | +5.1% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q4'26 | $5.2B | - | - |
| Q3'26 | $5.1B | $5.1B | +0.8% |
| Q2'26 | $5.4B | $5.4B | +0.5% |
| Q1'26 | $5.2B | $5.2B | +0.6% |
| Q4'25 | $5.3B | $5.3B | -0.9% |
| Q3'25 | - | $5.1B | - |
BSX|Monthly Returns
Market Data
BSX Stock Snapshot
- Market cap
- 65.26B
- P/E ratio
- 17.8
- Day range
- $42.78 – $44.41
- News sentiment
- 50/100 · Neutral
- Analyst target
- $49.60 (+14.9%)
- Consensus
- Buy · 38 analysts
BSX is on the weaker side of its setup, with little confirmation for a reversal yet. The stock is liquid enough that positioning changes get absorbed without distorting the trend.
Reverse DCF
What growth is priced into BSX?
At today's price, Boston Scientific Corporation needs to grow free cash flow about 5.1% a year for 3 years, slowing to a long-run rate by year 10, to justify its valuation at a 7.31% cost of capital. Over the last five years its revenue has trended at 14.2% a year, so the market is asking for 9.1 percentage points below its own delivered rate. On that basis BSX looks priced below what its own growth record supports.
- Implied FCF growth
- 5.1%
- Growth trend
- 14.2%
- Growth gap
- -9.1 pts
- Verdict
- CHEAP
- Discount rate (WACC)
- 7.31%
- Beta
- 0.77
Behaviour On Record
What BSX's own history says about today's numbers
- Realized volatility (21d)
- 42.3% 93rd pct
- Below its peak
- -57.6%
- vs 200-day average
- -17.6%
- Up days (1y)
- 46%
Boston Scientific Corporation is currently running 42.3% annualised volatility over the last 21 sessions. Measured against BSX's own 13 years of daily returns rather than a market-wide average, that is the 93rd percentile — an extreme by its own standards, against a typical reading of 23.4%.
BSX is trading -57.6% below its running peak. Across 13 full years on file, its median worst-drawdown-in-a-year was -17.7%, and the deepest was -57.7% in 2026. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began, and where past declines also continued.
Price sits -17.6% from its 200-day moving average. Against every other day in its history, that gap ranks at the 7th percentile — a narrower gap than it typically runs. Over the past year BSX closed higher on 46% of sessions, and it is currently 2 sessions into a rising streak.
On November specifically: over 13 years of records, BSX finished the month higher 6 of 13 times, with a median return of -2.8% and an average of -0.2%. Its strongest month historically has been January at +5.5% on average, its weakest September at -2.3%.
Overnight risk is measurable too: BSX has opened more than 2% away from the prior close in 123 of 3,268 sessions (3.8% of the time), with the largest gaps running +9.8% and -9.7%.
Across the last 4 dated reports on file, BSX moved an average of 1.3% in the session after earnings, closing higher 3 of those 4 times, with a median move of +1.2% and a largest of +2.1%.
All figures computed from 3,269 daily closes between 2013-11-06 and 2026-11-05, split-adjusted, recomputed daily. Percentiles are against BSX's own 13-year history, not a peer group or index.
Sector Rotation
Is money rotating into or out of BSX's sector?
Boston Scientific Corporation sits in the Health Care sector, currently ranked 1st of 12 GICS sectors by relative-strength rotation score (weakening). Within its narrower Medical Devices industry group, BSX ranks 1st of 15 tracked industries, leading.
- Sector rank
- #1 of 12
- Sector state
- Weakening
- Sector rotation score
- 100
- Industry rank
- #1 of 15
Analyst Consensus Estimates
What do analysts expect BSX to earn?
Analysts expect Boston Scientific Corporation to earn $3.18 per share in the fiscal year ending Dec 2026 and $3.49 in the fiscal year ending Dec 2029, from 2 estimates. These are analyst forecasts, not company guidance, and later years rest on fewer analysts.
Revenue marked ~ is our calculation from the EPS estimate, not analyst consensus.
Analyst Rating Changes
Are analysts turning bullish or bearish on BSX?
TD Cowen most recently downgraded Boston Scientific Corporation to Hold on Oct 30, 2026 with a price target of $46 (from $56). Over the last 90 days, coverage has run 0 upgrades against 3 downgrades, a net bearish lean.
- Latest action
- TD Cowen: Hold
- 90-day upgrades
- 0
- 90-day downgrades
- 3
- Net rating momentum
- -3
Earnings Release, Scored
What did Boston Scientific Corporation's latest earnings release say?
Most important lines
- 1
Received U.S. FDA 510(k) clearance for an expanded size offering of the SEISMIQ™ Intravascular Lithotripsy Peripheral Catheter to treat patients with severely calcified peripheral artery disease both above and below the knee.
New this quarter - 2
Received U.S. Food and Drug Administration (FDA) 510(k) clearance for two technologies within the StoneSmart™ Solutions ecosystem, including the Navigator™ Flex Ureteral Access Sheath Set , designed to enable the use of suction to remove kidney stone debris, and the LithoVue™ Elite Single-Use Digital Flexible Ureteroscope with temperature sensing , designed to display real-time fluid temperature alongside ureteroscopy video for procedural monitoring.
New this quarter - 3
As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of healthcare.
New this quarter
Peers & ETF holders
BSX peers & ETF holders
Medical DevicesMarket cap · today
News & sentiment
What is the news saying about BSX?
BSX rose 2.3% over the month to Nov 6. News tone held between 3 and 67 from Oct 6 to Oct 13, then jumped to 51 on Oct 14.
- Oct 28 -6.4%same day: Boston Scientific announces results for third quarter 2026
- Nov 2 +5.5%same day: Boston Scientific Consensus Price Target Lowered by 10.06% to $57.12
- Nov 4 +5.3%same day: Boston Scientific (BSX) Secures $455 Million For A Next Generation Heart Pump
Technical analysis
How strong is BSX's momentum right now?
On the daily chart BSX ranks at the 3rd percentile for momentum against 1,060 stocks and ETFs, a bearish reading.
Institutional ownership
Are big funds buying or selling BSX?
101 of the 243 tracked managers added to BSX in their latest 13F and 139 trimmed. Together they own 75.2% of the company, worth $48.9B. BlackRock and Vanguard Capital Management alone hold 15.0%.
- 1BlackRock, Inc.8.58%$5.5B positionTrimmed 1.6% last quarter
- $4.1B positionAdded 0.7% last quarter
- 3State Street Corp4.64%$3.0B positionAdded 3.1% last quarter
- 4PRIMECAP Management Co3.34%$2.2B positionAdded 55.3% last quarter
- 5FMR LLC (Fidelity)3.02%$2.0B positionTrimmed 38.4% last quarter
- $1.4B positionAdded 0.5% last quarter
- $1.3B positionTrimmed 0.0% last quarter
- 8D. E. Shaw & Co., Inc.1.68%$1.1B positionAdded 4.7% last quarter
- $1.5B positionAdded 126.1% last quarter
- 10JPMorgan Chase & Co1.58%$1.0B positionTrimmed 28.3% last quarter
Congressional trading
Is Congress trading BSX?
6 members of Congress disclosed 25 BSX trades between Jul 31, 2025 and Sep 9, 2026: 11 buys and 14 sells, about $383.0K in estimated value.
What stands out
Click one to highlight its trades in the chartDiscover more
How has BSX done against its peers?
Over the six months to Nov 6, BSX returned −22.9%. Of the 15 related stocks and ETFs, all did better, led by BDX at +44.6%.
- 1BDXBecton, Dickinson and Companyup 44.6%+67.6 pts
- 2GEHCGE HealthCare Technologies Inc.up 34.3%+57.2 pts
- 3DXCMDexCom, Inc.up 32.6%+55.5 pts
- 4MDTMedtronic plcup 31.3%+54.3 pts
- 5WSTWest Pharmaceutical Services, Inc.up 28.1%+51.0 pts
- 6XLVHealth Care Select Sector SPDR Fundup 27.5%+50.4 pts
- 7ZBHZimmer Biomet Holdings, Inc.up 25.7%+48.7 pts
- 8EWEdwards Lifesciences Corporationup 21.3%+44.2 pts
- 16BSXThis stockdown 22.9%